AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| 1 |
Netflix
NFLX
|
$530M |
| 2 |
Verisk Analytics
VRSK
|
$501M |
| 3 |
Otis Worldwide
OTIS
|
$454M |
| 4 |
lululemon athletica
LULU
|
$412M |
| 5 |
Microsoft
MSFT
|
$331M |
Top Sells
| 1 |
Apple
AAPL
|
$358M |
| 2 |
Arista Networks
ANET
|
$346M |
| 3 |
Nike
NKE
|
$317M |
| 4 |
Visa
V
|
$317M |
| 5 |
Cognizant
CTSH
|
$302M |
Sector Composition
| 1 | Technology | 27.72% |
| 2 | Healthcare | 18.03% |
| 3 | Financials | 11.05% |
| 4 | Consumer Discretionary | 10.27% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TVRD
3001
Tvardi Therapeutics, Inc. Common Stock
TVRD
$292M
| $157K | ﹤0.01% |
2,589
| – | – |
|
3002
Summit Therapeutics
SMMT
$19.3B
| $156K | ﹤0.01% |
83,226
+10,686
| +15% | +$20K |
|
3003
Sangamo Therapeutics
SGMO
$165M
| $152K | ﹤0.01% |
254,021
| – | – |
|
|
KLRS
3004
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.4M
| $152K | ﹤0.01% |
3,073
+451
| +17% | +$22.3K |
|
3005
Mineralys Therapeutics
MLYS
$2.7B
| $151K | ﹤0.01% |
15,860
+4,780
| +43% | +$45.5K |
|
3006
SkyWater Technology
SKYT
$491M
| $151K | ﹤0.01% |
25,040
+2,800
| +13% | +$16.9K |
|
3007
Semrush
SEMR
$1.15B
| $150K | ﹤0.01% |
17,690
+2,170
| +14% | +$18.4K |
|
3008
Xeris Biopharma Holdings
XERS
$1.27B
| $150K | ﹤0.01% |
80,420
+9,970
| +14% | +$18.5K |
|
3009
CarParts.com
PRTS
$60.1M
| $149K | ﹤0.01% |
36,200
| – | – |
|
3010
AirSculpt Technologies
AIRS
$367M
| $149K | ﹤0.01% |
21,760
+2,290
| +12% | +$15.7K |
|
|
API
3011
Agora
API
$310M
| $147K | ﹤0.01% |
58,295
+41,660
| +250% | +$105K |
|
3012
Quad
QUAD
$334M
| $140K | ﹤0.01% |
+27,920
| New | +$140K |
|
|
AEVA
3013
Aeva Technologies
AEVA
$786M
| $140K | ﹤0.01% |
36,572
-1,430
| -4% | -$5.47K |
|
3014
Olema Pharmaceuticals
OLMA
$570M
| $135K | ﹤0.01% |
+10,900
| New | +$135K |
|
3015
CureVac
CVAC
$1.21B
| $134K | ﹤0.01% |
+19,691
| New | +$134K |
|
3016
Hyliion Holdings
HYLN
$309M
| $133K | ﹤0.01% |
112,710
-14,730
| -12% | -$17.4K |
|
3017
Humacyte
HUMA
$226M
| $133K | ﹤0.01% |
45,330
+8,000
| +21% | +$23.4K |
|
|
CGAU
3018
Centerra Gold
CGAU
$1.76B
| $133K | ﹤0.01% |
27,100
| – | – |
|
3019
Luxfer Holdings
LXFR
$367M
| $132K | ﹤0.01% |
10,153
| – | – |
|
3020
Latham Group
SWIM
$960M
| $131K | ﹤0.01% |
46,850
+4,383
| +10% | +$12.3K |
|
3021
Terns Pharmaceuticals
TERN
$632M
| $131K | ﹤0.01% |
25,950
+5,230
| +25% | +$26.3K |
|
|
TIO
3022
DELISTED
Tingo Group, Inc. Common Stock
TIO
| $129K | ﹤0.01% |
126,040
-45,910
| -27% | -$47.1K |
|
3023
Eos Energy Enterprises
EOSE
$2.01B
| $128K | ﹤0.01% |
59,460
-59,460
| -50% | -$128K |
|
3024
Kodiak Sciences
KOD
$556M
| $128K | ﹤0.01% |
70,930
| – | – |
|
|
BHR
3025
Braemar Hotels & Resorts
BHR
$203M
| $127K | ﹤0.01% |
45,690
+810
| +2% | +$2.24K |
|